Literature DB >> 28527127

Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance.

Anika Mann1, Thomas Pelz1, Knut Rennert2, Alexander Mosig2, Michael Decker3, Amelie Lupp4.   

Abstract

HepaRG cells are widely used as an in vitro model to assess drug-induced hepatotoxicity. However, only few studies exist so far regarding their suitability to detect the effects of drugs requiring a preceding activation via the cytochrome P450 (CYP) system. A prototypic substance is the anti-tuberculosis agent INH, which is metabolized into N-acetylhydrazine, which then triggers hepatotoxicity. Therefore, the aim of the present study was to test if this effect can also be detected in HepaRG cells and if it can be counteracted by the known hepatoprotectant silibinin. For this purpose, differentiated HepaRG cells were treated with increasing concentrations of INH (0.1-100 mM) or 10 mM INH plus escalating concentrations of silibinin (1-100 µM). After 48 h of treatment, cell morphology and parameters indicating cell vitality, oxidative stress, and liver cell function were assessed. High concentrations of INH led to severe histopathological changes, reduced cell vitality and glutathione content, increased LDH and ASAT release into the medium, enhanced lipid peroxidation, and elevated cleaved caspase-3 expression. Additionally, glycogen depletion and reduced biotransformation capacity were seen at high INH concentrations, whereas at low concentrations an induction of biotransformation enzymes was noticed. Silibinin caused clear-cut protective effects, but with few parameters INH toxicity was even aggravated, most probably due to increased metabolization of INH into its toxic metabolite. In conclusion, HepaRG cells are excellently suited to evaluate the effects of substances requiring prior toxification via the CYP system, such as INH. They additionally enable the identification of complex substance interactions.

Entities:  

Keywords:  Cytochrome P450; HepaRG cells; Hepatotoxicity; INH; Oxidative stress; Silibinin

Mesh:

Substances:

Year:  2017        PMID: 28527127     DOI: 10.1007/s13577-017-0175-9

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  69 in total

Review 1.  Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge.

Authors:  S Knasmüller; V Mersch-Sundermann; S Kevekordes; F Darroudi; W W Huber; C Hoelzl; J Bichler; B J Majer
Journal:  Toxicology       Date:  2004-05-20       Impact factor: 4.221

Review 2.  Evolving concepts in liver tissue modeling and implications for in vitro toxicology.

Authors:  André Guillouzo; Christiane Guguen-Guillouzo
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-10       Impact factor: 4.481

3.  Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study.

Authors:  Sebastian Klein; Daniel Mueller; Valery Schevchenko; Fozia Noor
Journal:  J Appl Toxicol       Date:  2013-09-30       Impact factor: 3.446

Review 4.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.

Authors:  E L LeCluyse
Journal:  Eur J Pharm Sci       Date:  2001-07       Impact factor: 4.384

Review 5.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

Authors:  André Guillouzo; Anne Corlu; Caroline Aninat; Denise Glaise; Fabrice Morel; Christiane Guguen-Guillouzo
Journal:  Chem Biol Interact       Date:  2006-12-16       Impact factor: 5.192

6.  Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells.

Authors:  Marc Le Vee; Gregory Noel; Elodie Jouan; Bruno Stieger; Olivier Fardel
Journal:  Toxicol In Vitro       Date:  2013-07-12       Impact factor: 3.500

7.  Differential toxicity of heterocyclic aromatic amines and their mixture in metabolically competent HepaRG cells.

Authors:  Julie Dumont; Rozenn Jossé; Carine Lambert; Sébastien Anthérieu; Ludovic Le Hegarat; Caroline Aninat; Marie-Anne Robin; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Toxicol Appl Pharmacol       Date:  2010-03-20       Impact factor: 4.219

Review 8.  Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.

Authors:  Alimuddin Zumla; Jeremiah Chakaya; Rosella Centis; Lia D'Ambrosio; Peter Mwaba; Matthew Bates; Nathan Kapata; Thomas Nyirenda; Duncan Chanda; Sayoki Mfinanga; Michael Hoelscher; Markus Maeurer; Giovanni Battista Migliori
Journal:  Lancet Respir Med       Date:  2015-03-09       Impact factor: 30.700

9.  Long-term administration of Silymarin augments proinflammatory mediators in the hippocampus of rats: evidence for antioxidant and pro-oxidant effects.

Authors:  H Malekinejad; F Rahmani; S Valivande-Azar; M Taheri-Broujerdi; B Bazargani-Gilani
Journal:  Hum Exp Toxicol       Date:  2012-02-21       Impact factor: 2.903

10.  Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.

Authors:  G R Sarma; C Immanuel; S Kailasam; A S Narayana; P Venkatesan
Journal:  Am Rev Respir Dis       Date:  1986-06
View more
  4 in total

Review 1.  Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives.

Authors:  Lucija Kuna; Ivana Bozic; Tomislav Kizivat; Kristina Bojanic; Margareta Mrso; Edgar Kralj; Robert Smolic; George Y Wu; Martina Smolic
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

Review 2.  Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Lina Tao; Xiaoyu Qu; Yue Zhang; Yanqing Song; Si-Xi Zhang
Journal:  Can J Gastroenterol Hepatol       Date:  2019-01-10

3.  Xiao-Yao-San protects against anti-tuberculosis drug-induced liver injury by regulating Grsf1 in the mitochondrial oxidative stress pathway.

Authors:  Zijun Bai; Weiwei Tao; Yiqun Zhou; Yi Cao; Shun Yu; Zheng Shi
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

4.  An Evaluation of the In Vitro Roles and Mechanisms of Silibinin in Reducing Pyrazinamide- and Isoniazid-Induced Hepatocellular Damage.

Authors:  Zhang-He Goh; Jie Kai Tee; Han Kiat Ho
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.